GENELABS TECHNOLOGIES, INC.

NEWS RELEASE

CONTACT:

Andrea A. Boscoe
Genelabs Technologies, Inc.
415-369-9592 ext. 303

Mark Brand
Pondel Parsons & Wilkinson
310-207-9300

FOR IMMEDIATE RELEASE

GENELABS BEGINS PHASE II/III NEW DRUG TRIAL FOR LUPUS

Redwood City, California—May 10, 1994— Genelabs Technologies, Inc. (Nasdaq: GNLB) today announced the start of a randomized, double-blind, placebo controlled, multi-center, Phase II/III clinical trial of GL701-DHEA (dehydroepiandrosterone) for the treatment of mild to moderate systemic lupus erythematosus (SLE, lupus) in women who require prednisone or other steroids for their treatment. GL701 is one of three drugs in clinical trials for Genelabs.

Lupus is a chronic, autoimmune disease of unknown cause that damages the kidneys, nervous system, skin, joints, and linings of the lungs, heart and other organs. Lupus occurs predominantly in young women.

Current therapy for lupus consists mainly of prednisone, the use of which is associated with significant adverse effects including premature osteoporosis, atherosclerosis, psychosis and increased incidence of infection due to immunosuppression.

"Based on earlier studies performed at Stanford University Medical Center, we believe that GL701 is a potential product which may improve the quality of life for lupus patients through reduction of prednisone usage," said Irene Chow, Ph.D. president of Genelabs' biopharmaceutical division.

Established in 1984, Genelabs Technologies, Inc. is a global biopharmaceutical and diagnostic company. Genelabs is developing therapeutic and vaccine products for viral diseases, autoimmune disorders and other life-threatening or debilitating conditions, and is developing and marketing a portfolio of viral diagnostic products. Genelabs has 220 employees in facilities located in Redwood City, California; San Antonio, Texas; Morris Plains, New Jersey; Geneva, Switzerland; Leuven, Belgium; Taiwan, ROC; and Singapore.

###